A Proof-of-Concept Clinical Trial of Intratumoral Injection of GLA-SE, a Toll-like Receptor-4 Agonist, in Patients With Merkel Cell Carcinoma
Phase of Trial: Phase I
Latest Information Update: 09 Aug 2018
Price : $35 *
At a glance
- Drugs Glycopyranosyl lipid adjuvant (Primary)
- Indications Merkel cell carcinoma
- Focus Adverse reactions; First in man; Proof of concept
- Sponsors Immune Design
- 09 Aug 2018 Results assessing the safety, efficacy, and immunologic activity published in the Clinical Cancer Research
- 11 Jun 2018 Status changed from active, no longer recruiting to completed.
- 15 Aug 2017 Planned End Date changed from 1 Jan 2017 to 1 Dec 2017.